Compare Fabrinet (FN) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Fabrinet trades at $486.28 (market cap $17.46B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Fabrinet is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| FN | HALO | |
|---|---|---|
Market Cap | $17.46B | $12.58B |
Volume | 1,199,886 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $746.47 | $115.22 |
52-Week Low | $361.94 | $61.63 |
Typical Hold Time | 30 Days | 1 Days |
Enterprise Value | $16.59B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $487.33, down 2.14% on the day, amid a mixed technical backdrop with a bullish moving average signal but overbought RSI readings. Fundamentally, the company demonstrates strong profitability with a 10.19% net income margin and 21.33% ROE, supported by consecutive quarterly EPS beats. Recent news highlights surging AI data center demand driving revenue growth, though the stock faces pressure from high capital expenditures and customer concentration concerns.
The outlook remains positive given robust analyst sentiment (75% buy ratings) and a consensus price target of $769.50, implying significant upside. Key opportunities include capacity expansion to capture AI infrastructure growth, while risks involve margin compression from spending and reliance on a few hyperscaler customers. Earnings acceleration and market positioning support a constructive view, but volatility may persist near-term.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
